ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "skin"

  • Abstract Number: 0557 • ACR Convergence 2021

    The Beta Secretase BACE1 Induces Systemic Sclerosis (SSc) Fibroblast Activation Through the Regulation of the Pro-Fibrotic Notch Signalling Pathway

    Christopher Wasson1, Eva Clavane2, Rebecca Ross1, Paul Meakin2 and Francesco Del Galdo3, 1LIRMM University of Leeds, Leeds, United Kingdom, 2LICAMM University of Leeds, Leeds, United Kingdom, 3University of Leeds, Leeds, United Kingdom

    Background/Purpose: Extensive work in the Alzheimer’s field has shown BACE1 plays an important role in amyloid beta processing. Additionally, there is evidence showing BACE1 regulating…
  • Abstract Number: L09 • ACR Convergence 2020

    A Phase 2a Randomized, Double-blind, Placebo-controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis (NOVESA)

    Dinesh Khanna1, Christopher Denton2, Daniel Furst3, Maureen Mayes4, Marco Matucci-Cerinic5, Vanessa Smith6, Dick de Vries7, Liesbeth Deberdt8, Pieter‑Jan Stiers8, Niyati Prasad8 and Sohail Ahmed9, 1University of Michigan, Ann Arbor, MI, 2Royal Free Hospital, University College London, London, United Kingdom, 3David Geffen School of Medicine at UCLA, Los Angeles, CA, 4University of Texas Health Science Center at Houston, Houston, TX, 5Università degli Studi di Firenze, Firenze, Italy, 6Ghent University Hospital, Ghent, Belgium, 7Galapagos BV, Leiden, Netherlands, 8Galapagos NV, Mechelen, Belgium, 9Ahmed Science Medicine, Basel, Switzerland

    Background/Purpose: There is a high unmet need for systemic sclerosis (SSc) treatments. Ziritaxestat (ziri; GLPG1690) is an autotaxin inhibitor with a novel mechanism of action.…
  • Abstract Number: L10 • ACR Convergence 2020

    Targeting Plasmacytoid Dendritic Cells Improves Cutaneous Lupus Erythematosus Skin Lesions and Reduces Type I Interferon Levels: Results of a Phase 1 Study of VIB7734

    Victoria Werth1, Jodi Karnell2, William Rees2, Nanette Mittereder3, Li Yan2, Yanping Wu3, Jorn Drappa2, Gabor Illei2 and John Ratchford2, 1University of Pennsylvania, Philadelphia, PA, 2Viela Bio, Gaithersburg, MD, 3Viela Bio, Gaithersburg

    Background/Purpose: Plasmacytoid dendritic cells (pDCs) secrete large amounts of type I interferon (IFN) and other cytokines upon activation. pDCs migrate to sites of active disease…
  • Abstract Number: 1397 • ACR Convergence 2020

    Clinical and Demographic Features of Morphea Patients with Mucocutaneous Involvement: A Cross Sectional Study from the Morphea of Adults and Children Cohort

    Smriti Prasad1, Samantha Black2, Shivani Sharma3 and Heidi Jacobe1, 1University of Texas Southwestern Medical Center, Dallas, TX, 2The University of Texas Southwestern Medical Center, Dallas, TX, 3University of Texas Southwestern, Dallas, TX

    Background/Purpose: Morphea is an autoimmune skin condition that produces skin and soft tissue sclerosis. While clinical manifestations of morphea have been well-described, mucocutaneous findings such…
  • Abstract Number: 1610 • ACR Convergence 2020

    Cutaneous Side Effects of Hydroxychloroquine in Rheumatic Diseases –Combination of “Traditional” Multivariate Analysis for Risk Factors AndClassification Model Development Using Supervised Machine Learning –Single Centre Retrospective Cohort Study in India

    Sandeep Surendran1, Mithun CB1, Arun Tiwari2, Vishal Marwaha1 and Sekhar Easwar1, 1Amrita Institute of Medical Sciences, Kochi, Kerala, India., Kochi, Kerala, India, 2Amrita Institute of Medical Sciences, Kochi, Kerala, India., Kochi, India

    Background/Purpose: Hydroxychloroquine (HCQ) is associated with varied cutaneous side effects but only few studies in literature characterizing the risk factors for this. Recently machine learning…
  • Abstract Number: 0076 • ACR Convergence 2020

    The Role of Interferon Kappa in Psoriasis

    Mehrnaz Gharaee-Kermani1, Shannon Estadt2, Sonya Wolf-Fortune1, Jianhua Liu1, Tamra Reed3, Johann Gudjonsson4 and J. Michelle Kahlenberg5, 1University of Michigan, Ann Arbor, MI, 2University of Michigan, Ypsilanti, MI, 3University of Michigan, Ann Arbor, 4University of Michigan, Ann ArborUniversity of Michigan, 5Division of Rheumatology, University of Michigan, Ann Arbor, MI

    Background/Purpose: Psoriasis is a common, chronic inflammatory autoimmune skin diseases characterized by hyperproliferation and abnormal differentiation of keratinocytes and infiltration of inflammatory cells. Early infiltration…
  • Abstract Number: 1631 • ACR Convergence 2020

    No Increased Risk of Liver Dysfunction from Tildrakizumab Treatment: Post Hoc Analyses of the Tildrakizumab Psoriasis Clinical Program

    Mark Lebwohl1, Darren West2, Alan Mendelsohn3, Stephen Rozzo3 and Giampiero Girolomoni4, 1Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, 2Spectrum Dermatology, Scottsdale, AZ, 3Sun Pharmaceutical Industries, Inc., Princeton, NJ, 4Section of Dermatology, Department of Medicine, University of Verona, Verona, Italy

    Background/Purpose: Tildrakizumab (TIL) is a high‐affinity, humanized, immunoglobulin G1κ, anti–interleukin-23p19 monoclonal antibody approved for the treatment of moderate to severe plaque psoriasis. We evaluated adverse…
  • Abstract Number: 0263 • ACR Convergence 2020

    Factors Associated with Disease Activity Remission and Recurrence in Cutaneous Lupus Erythematosus

    Stephanie Florez-Pollack1, Syed Rizvi2, Benjamin Chong2 and Linda Hynan2, 1University of Pennsylvania, PHILADELPHIA, PA, 2University of Texas Southwestern Medical Center, Dallas, TX

    Background/Purpose: Cutaneous lupus erythematosus (CLE) is a photosensitive skin disorder that can occur with systemic lupus erythematosus. As CLE often fluctuates in disease activity, little…
  • Abstract Number: 1802 • ACR Convergence 2020

    Vitamin D Level: Predictor of SLE Disease Activity in AA Cohort with CLE?

    Ileannette Robledo-Vega1, John Scheinuk2, Emmanuel Pardo2, Ansley Pratt2, Soham Mahato3, Andrew G. Chapple2 and Myriam Guevara4, 1Louisiana State University Health Sciences Center, New Orlenas, LA, 2Louisiana State University, New Orleans, LA, 3LSUHSC School of Public Health, New Orleans, LA, 4Lousiana State University Health Sciences Center, New Orleans, LA

    Background/Purpose: There are few predominant African American (AA) epidemiological studies in Cutaneous Lupus Erythematosus (CLE). The Gilliam classification divides CLE into lupus specific, acute cutaneous…
  • Abstract Number: 0283 • ACR Convergence 2020

    Genome-wide DNA Methylation Analysis in Lupus Keratinocytes Identifies Differential Methylation of Genes That Regulate Apoptosis

    Grace Hile1, Patrick Coit1, Chang Zeng1, Rachael Wasikowski2, Alex Tsoi2, Allison Billi2, Johann Gudjonsson3, Amr Sawalha4 and J. Michelle Kahlenberg5, 1University of Michigan, Ann Arbor, MI, 2University of Michigan, Ann ARbor, 3University of Michigan, Ann ArborUniversity of Michigan, 4University of Pittsburgh, Pittsburgh, 5Division of Rheumatology, University of Michigan, Ann Arbor, MI

    Background/Purpose: Cutaneous lupus erythematous (CLE) is a disfiguring manifestation of systemic LE (SLE), and the pathogenesis remains unclear. However, epidermal regulation of skin inflammation and…
  • Abstract Number: 1906 • ACR Convergence 2020

    Hsp90 Inhibition Effectively Prevents Progression of Dermal Fibrosis and Induces Regression of Established Bleomycin-Induced Dermal Fibrosis

    Hana Storkanova1, Lenka Storkanova2, Sabina Oreska3, Maja Spiritovic4, Barbora Hermankova5, Radim Becvar1, Karel Pavelka6, Jiří Vencovský6, Jörg HW Distler7, Ladislav Šenolt6 and Michal Tomcik1, 1Institute of Rheumatology, Prague, Czech Republic. Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, 2Institute of Rheumatology, Prague, Czech Republic, 3Institute of Rheumatology, Prague, Czech Republic. Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Praha 2, Czech Republic, 4Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, Prague, Czech Republic, 5Faculty of Physical Education and Sport, Department of Physiotherapy, Charles University, Prague, Czech Republic,, Prague, Czech Republic, 6Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 7University of Erlangen-Nuremberg, Erlangen, Germany, Erlangen, Germany

    Background/Purpose: Our previous study demonstrated that Heat shock protein 90 (Hsp90) is overexpressed in the skin of patients with systemic sclerosis (SSc), in cultured SSc…
  • Abstract Number: 0284 • ACR Convergence 2020

    Oxidative DNA Damage Accelerates Skin Inflammation in Pristane-induced Lupus Model

    Gantsetseg Tumurkhuu1, Shuang Chen2, Erica Montano1, Malcolm Lane2, Michifumi Yamashita2, Janet Markman2, Luz Blanco3, Mariana Kaplan4, Kenichi Shimada2, Timothy Crother2, Mariko Ishimori2, Daniel J Wallace1, Caroline Jefferies5 and Moshe Arditi2, 1Cedars-Sinai Medical Center, Los Angeles, 2Cedars-Sinai Medical Center, Los Angeles, CA, 3National Institute of Arthritis and Musculoskeletal and Skin Diseases, Centreville, 4National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, 5Cedars-Sinai Medical Center, West Hollywood, CA

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic inflammatory autoimmune disease in which type I interferons (IFN) play a key role. The IFN response can…
  • Abstract Number: 2033 • ACR Convergence 2020

    Large-scale Examination of Longitudinal Skin Gene Expression and Its Associations with Skin Thickness in Systemic Sclerosis

    Brian Skaug1, Marka Lyons1, William Swindell2, Gloria Salazar1, Julio Charles1, Connor Vershel1, Maureen Mayes3 and Shervin Assassi3, 1University of Texas Houston, McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX, 2The Jewish Hospital, Department of Internal Medicine, Cincinnati, OH, 3University of Texas Houston McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX

    Background/Purpose: Numerous studies have revealed dysregulated gene expression in the skin of systemic sclerosis (SSc) patients, with varying degrees of inflammatory/immune and fibroblast upregulation.  However,…
  • Abstract Number: 0318 • ACR Convergence 2020

    Oxylipin Profile Is Associated with Skin Disease and Enthesitis in Psoriatic Disease

    Roxana Coras1, Arthur Kavanaugh2, Angela Kluzniak3, Dustina Holt3, Amy Weilgosz3, Oswald Quehenberger1, Christopher Ritchlin4 and Monica Guma5, 1University of California San Diego, La Jolla, CA, 2Division of Rheumatology, Allergy, & Immunology, University of California San Diego Medical School, San Diego, CA, 3University of Rochester Medical Center, New York, NY, 4Department of Medicine, University of Rochester Medical Center, Rochester, NY, 5Division of Rheumatology, University of California San Diego, Department of Medicine, Autonomous University of Barcelona, La Jolla, CA

    Background/Purpose: Psoriatic arthritis (PsA), a systemic inflammatory disease, occurs in about 25% of patients with psoriasis (PsO). At present, there are no biomarkers that reliably…
  • Abstract Number: 0378 • ACR Convergence 2020

    Itch as the Major Mediator of the Effect of Tofacitinib on Health-Related Quality of Life in Psoriatic Arthritis: A Mediation Analysis

    Joseph Merola1, Peter Taylor2, Andrew Bushmakin3, Joseph Cappelleri3, Pamela Young4, Rebecca Germino5 and Gil Yosipovitch6, 1Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, 2Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, 3Pfizer Inc, Groton, CT, 4Pfizer Inc, Collegeville, PA, 5Pfizer Inc, New York, NY, 6University of Miami, Miami, FL

    Background/Purpose: Psoriatic arthritis (PsA) is a chronic, systemic inflammatory disease with signs and symptoms across multiple domains, including cutaneous manifestations, which can impact health-related quality…
  • « Previous Page
  • 1
  • …
  • 9
  • 10
  • 11
  • 12
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology